TY - JOUR T1 - The most fundamental change in asthma management in 30 years? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01583-2019 VL - 54 IS - 5 SP - 1901583 AU - Israel Amirav AU - Michael T. Newhouse Y1 - 2019/11/01 UR - http://erj.ersjournals.com/content/54/5/1901583.abstract N2 - We would like to raise our considerable concern regarding a potential major change in the management of exacerbations of asthma which is soon to be discussed in the European Union (EU). The Global Initiative for Asthma (GINA) has recently changed their recommendation regarding management of patients with mild asthma. Instead of using only short-acting β2-agonist (SABA) as needed, GINA suggests that all patients should also be using inhaled corticosteroids (ICS) simultaneously. This was based on a few studies that have used “as needed” ICS/long-acting β2-agonist (LABA) for acute asthma. A group of authors has hailed this change as “the most fundamental change in asthma management in 30 years” and explained, in detail, the reasons for the change in an article recently published in the European Respiratory Journal [1].Changes in GINA guidelines should be confirmed by an independent body of experts in asthma management http://bit.ly/2zbUHp8 ER -